Article Text

Download PDFPDF

Viral hepatitis
PMO-182 HCV research UK: a UK national resource to support research into HCV infection
Free
  1. W Irving1,
  2. J McLauchlan2,
  3. G Foster3,
  4. J Dillon4,
  5. S Hutchinson5,
  6. B Wilkes1
  1. 1University of Nottingham, Nottingham, UK
  2. 2MRC/University of Glasgow Centre for Virus Research, Glasgow, UK
  3. 3University of London, London, UK
  4. 4University of Dundee, Dundee, UK
  5. 5Health Protection Scotland, Glasgow, UK

Abstract

Introduction Background: Hepatitis C virus (HCV) infection has been identified by the MRC and Department of Health MRC as a priority area for research and development to meet the clinical challenges posed by the scale of the infection in the UK. There has been a perceived lack of connection between clinicians and basic scientists working on HCV in the UK to address this problem. Aims: To create a multi-disciplinary consortium comprising clinicians and non-clinical scientists to encourage translational research. To establish a cohort of 10 000 patients with HCV infection across the UK, together with clinical database and biorepository—“HCV Research UK”. To make this resource available to researchers, both academic/commercial, UK-based and abroad.

Methods Aims: Our objective has been to create a multi-disciplinary consortium comprising clinicians and non-clinical scientists to encourage translational research into the factors that determine outcome of infection, treatment response and disease progression. We aim to establish a cohort of 10 000 patients with HCV infection from across the UK that is supported by the necessary systems to make clinical data and specimens available to academic and commercial researchers, both in the UK and abroad.

Results Progress: HCV Research UK has been funded by the Medical Research Foundation (£1.92 million) to establish an infrastructure that connects 18 clinical centres who will recruit 10 000 HCV-infected patients. The key elements of the infrastructure are a bespoke clinical research database, which is linked to a biorepository of samples that will hold serum, PBMCs and DNA from patients. Access to data and samples is managed by a Tissue and Data Access Committee who have the authority to grant ethical approval for research using the resource. The study has been given CLRN portfolio status.

Conclusion Future plans: Recruitment of patients will begin in early 2012 and grant applications have been submitted to (1) Wellcome/Department of Health Innovation Challenge fund (2) MRC call for Stratified Medicine (3) BLT Research call (4) NIHR Programme Development award schemes for research using the resource. It is hoped that portfolio support will provide a mechanism for new centres to join the consortium.

Competing interests None declared.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.